SUVENPHAR Suven Pharmaceuticals Ltd Earnings Reports Announcement 2025 - Q3 Earnings Report Suven Pharmaceuticals Ltd reported a 40% YoY revenue growth in Q3 FY25, achieving adjusted EBITDA margins of 38.7% on a proforma basis with reported revenue of Rs 6.76bn for Suven+Cohance, while standalone revenue was Rs 3.07bn with margins of 44.9%..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Suven Pharmaceuticals Ltd